News Releases

—HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th— —Roth Conference at 10:00 am ET on March 15th— —Oppenheimer Healthcare Conference at 1:50 pm ET on March 17th—

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive...

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved...

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive...

--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count-- VANCOUVER, BC, Dec. 7, 2020 /CNW/ - Sierra Oncology,...

--Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC, Dec. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a...

--Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kiladjian, Ruben Mesa and Srdan Verstovsek-- VANCOUVER, BC, Dec. 1, 2020 /CNW/ -...

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address...

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address...

- Efficacy data for momelotinib in myelofibrosis patients by baseline platelet levels also to be presented - VANCOUVER, BC, Nov. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage...

- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - VANCOUVER, BC, Nov. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of...

- Kevin Norrett appointed Chief Business Officer – - William D. Turner appointed Chief Regulatory and Technical Operations Officer – VANCOUVER, BC, Aug. 6, 2020 /CNW/ - Sierra Oncology, Inc....

- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - - Updated analyses comparing symptomatic benefits of momelotinib to ruxolitinib from the SIMPLIFY-1...

- Ms. Thomson brings extensive strategic, transactional and intellectual property experience as Sierra prepares for potential transition into a commercial company - VANCOUVER, British Columbia,...

- Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib - -...

- Oppenheimer Biotech by the Lake 2020 Investor Summit at 11:25 a.m. ET on May 28th – - Jefferies Global Virtual Healthcare Conference at 4:30 p.m. ET on June 3rd - VANCOUVER, May 27, 2020 /CNW/...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

- Momelotinib's demonstrable anemia benefit and low myelosuppressive potential facilitate sustained dose intensity and prolonged clinical activity - - Long-term safety profile reinforces lack of...

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 10:00 am ET on Wednesday, May 13th - VANCOUVER, May 7, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug...

- Company continues to operationalize the MOMENTUM Phase 3 clinical trial in myelofibrosis - - Impact of COVID-19 uncertain but may potentially affect overall MOMENTUM timelines - - Publications...

- MOMENTUM Phase 3 clinical trial for momelotinib underway, targeting enrolment of 180 patients with myelofibrosis who are symptomatic and anemic - - Publications highlighting durability, safety...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

-"Building MOMENTUM for Patients with Myelofibrosis" scheduled for 10:00 a.m. ET on March 4, 2020 - VANCOUVER, Feb. 25, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

- Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement -...

- New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting - - Analyst &...

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8th - - Data highlighting decreased transfusion requirements for patients treated with...

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

- MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen - - Targeting enrollment of 180 symptomatic...

- "Building Momentum for Patients with Myelofibrosis" scheduled for 6:00 p.m. GMT on November 20, 2019 - VANCOUVER, Nov. 14, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug...

- Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra - - Amendments become effective upon Sierra Oncology closing a qualified financing - VANCOUVER, Nov. 7,...

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

- New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated...

- MOMENTUM Phase 3 myelofibrosis clinical trial anticipated to launch in Q4 2019 - VANCOUVER, Nov. 4, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on...

- Sierra preparing to launch the MOMENTUM Phase 3 myelofibrosis clinical trial expected in Q4 2019 - - Exploring non-dilutive options to support future continued development of DDR portfolio -...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...

- Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Exploring non-dilutive options to support future continued development of SRA737 and SRA141 -...

- Fast Track designation highlights the potential for momelotinib to address the significant unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK...

- MOMENTUM Phase 3 clinical trial planned for launch in Q4 2019; topline efficacy data anticipated in Q4 2021 – - World renowned myelofibrosis expert Dr. Srdan Verstovsek named Chief...

- Sierra management and distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit discuss clinical findings and possible next steps for SRA737 - - Sierra reported SRA737...

- Sierra reports 30% response rate for SRA737+LDG in anogenital cancer - - Anti-cancer activity demonstrated across multiple indications and genetic contexts in preliminary Phase 1/2 data...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1st - - Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3rd...

Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER, May 8, 2019 /CNW/ - Sierra...

Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...

- Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action - VANCOUVER, April 3, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA),...

- Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung...